{{Rsnum
|rsid=10192566
|Gene=LPIN1
|Chromosome=2
|position=11750302
|Orientation=plus
|GMAF=0.4734
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=LPIN1
}}A total of 262 Korean [[type-2 diabetes]] patients were treated with 12 weeks of [[rosiglitazone]] at 4mg/day and genotyped to reveal that [[rs10192566]](G) allele carriers responded better than (C) carriers. Patients with [[rs10192566]](G) alleles had a larger decrease in fasting plasma glucose, 2-h postprandial glucose, and HbA1c than [[rs10192566]](C;C) homozygotes. None of the other [[LPIN1]] gene SNPs tested were associated with response.{{PMID|18693052}} 

Note: [[rs11693809]], [[rs10192566]], and [[rs2278513]] are in nearly complete linkage disequilibrium (D'>0.958, r(2) >0.882).

{{PharmGKB
|RSID=rs10192566
|Name_s=
|Gene_s=LPIN1
|Feature=
|Evidence=PubMed ID:18693052
|Annotation=A study in patients with type 2 diabetes treated with rosiglitazone showed that this SNP in the LPIN1 gene was significantly associated with rosiglitazone treatment response. rs11693809 and rs2278513 are in nearly complete linkage disequilibrium with rs10192566.
|Drugs=rosiglitazone
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA162316734
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10192566
|overall_frequency_n=74
|overall_frequency_d=128
|overall_frequency=0.578125
|n_genomes=45
|n_genomes_annotated=0
|n_haplomes=64
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}